Maze (MAZE) CEO Jason Coloma Sells 34,501 Shares

What Happened
Maze Therapeutics CEO Jason V. Coloma sold a total of 34,501 Maze shares in open-market/private sales on August 3, 2026, generating aggregate proceeds of roughly $922,315. The filing reports four disposals: 2,439 shares at a weighted avg $26.71 ($65,157), 154 shares at $27.09 ($4,172), 30,304 shares at $26.71 ($809,541), and 1,604 shares at $27.09 ($43,445). All transactions are coded as sales (S).

Key Details

• Transaction date: 2026-08-03; Form 4 filed: 2026-08-05 (appears timely).
• Sales detail (per filing):
  • 2,439 shares @ $26.71 = $65,157
  • 154 shares @ $27.09 = $4,172
  • 30,304 shares @ $26.71 = $809,541
  • 1,604 shares @ $27.09 = $43,445
  • Total: 34,501 shares for ~$922,315.
• Reported prices are weighted averages; actual trade prices occurred across ranges noted in the filing (approximately $26.005 to $27.19 per share).
• Some sales were effected pursuant to a Rule 10b5-1 trading plan adopted Feb 6, 2026 (F1).
• Some of the sold shares were held in trusts (The Coloma 2021 Irrevocable Trust and the Coloma Family Trust — F3, F6).
• Shares owned after the transaction are not specified in the provided summary of the filing.

Context

• These are outright sales (not exercises or awards). Sales under a pre-established 10b5-1 plan and transfers from trusts are commonly routine and do not necessarily indicate a change in the insider’s view of the company.
• The filing is informational; retail investors should consider insider activity alongside company fundamentals and broader market context rather than viewing sales alone as a clear signal.